Lenvatinib, a potent multikinase inhibitor targeting VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET, requires ultra-high synthesis precision. Our OEM factories leverage advanced chromatography to ensure >99.8% purity, meeting USP/EP standards.
Our 250,000 sqm facility integrates automated flow chemistry and AI-driven quality monitoring. This "Smart Factory" model reduces batch-to-batch variation by 15% while maintaining a resilient supply chain against global market fluctuations.
Gentolex operates under strict cGMP guidelines. We provide full CTD dossier support (DMF/CEP) and maintain representative offices in Mexico and South Africa for localized regulatory navigation.
The oncology therapeutic landscape is shifting towards personalized medicine. As a leading OEM Lenvatinib Factory, we are transitioning from raw API supply to high-complexity formulation development.
R&D focused on Lenvatinib lipid nanoparticles (LNPs) to improve bioavailability and reduce systemic toxicity, providing a blueprint for next-decad oncology drugs.
Implementing solvent-free reactions and enzymatic catalysts to reduce the environmental footprint of Lenvatinib production by 40% by 2026.
Developing synergistic API co-crystals that combine Lenvatinib with PD-1 inhibitors for enhanced efficacy in hepatocellular carcinoma (HCC) treatments.
An overall factory construction area of 250,000 square meters under international standard to offer flexible, scalable and cost-effective solutions.
Gentolex offers an extensive range of APIs and intermediates for development study and commercial application with cGMP standard from long-term collaborations.
Customized procurement services with superior supply chain sources to avoid the complexity of dealing with multiple points of contact.
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specially, representatives are established in Mexico and South Africa. Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
Introduction to Selank Acetate API as a synthetic heptapeptide active pharmaceutical ingredient for neuropharmacological research.
View Details
High-quality Tβ4 peptide API solutions for biotechnology companies and pharmaceutical research organizations worldwide.
View Details
Synthetic pentadecapeptide research focusing on tissue repair and gastrointestinal protection mechanisms.
View Details
Neuroactive peptides derived from ACTH fragments, attracting attention in modern neuroscience investigations.
View Details
Mitochondria-targeting tetrapeptide designed to stabilize mitochondrial structure and support bioenergetics.
View DetailsWith hubs in Mexico and South Africa, we bridge the gap between Chinese manufacturing efficiency and local regulatory frameworks, ensuring seamless market entry.
Our vertical integration—from intermediate raw materials to finished APIs—minimizes external shocks and price volatility for long-term contract partners.
We offer Finished Dosage Form (FDF) licensing opportunities, providing comprehensive dossiers for local marketing authorization holders.
A: We guarantee a minimum purity of 99.5% via HPLC, with impurity profiles strictly controlled according to international ICH guidelines.
A: Our regulatory affairs team provides eCTD format dossiers, including DMF, CEP, and ASMF, tailored to the requirements of the FDA, EMA, and NMPA.
A: Yes, our technical support team assists in lab setup and product line development for specific dosage forms including capsules and innovative oral solutions.
A: For standard API orders, lead times typically range from 2-4 weeks, depending on the volume and specific customization requirements.
